ReviewHeliyon2023
An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker.
Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy is a treatment that uses the body's own immune system to fight against cancer. Malignant cells in the human body have the ability to mutate themselves in such a way that they can escape from immune system surveillance and proliferate. So, if the human immune system could be boosted or its surveillance and defensive mechanisms improved so that our bodies can detect cancer cells and kill them by combining all of the human body's defensive mechanisms, it would be much easier to deal with cancer. A recent trial at Memorial Sloan Kettering Cancer Center in New York found that by using a drug called Dostarlimab, rectal adenocarcinoma could be cured by boosting the human immune system to detect and kill cancer cells. This could be considered a validated extension of cancer immunotherapy. This paper will explain how dostarlimab works on the body's immune system and destroys cancer cells in a simple way that anyone who is not in the medical field also can understand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.